NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes. The company also operates Cellaviva, a stem cell bank; and QVance, the first dedicated provider of quality services for developers of advanced therapies. The company was incorporated in 2014 and is headquartered in Huddinge, Sweden.
Frequently asked questions
What sector does NextCell Pharma AB (NXTCL) operate in?
NextCell Pharma AB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is NextCell Pharma AB (NXTCL) current stock price?
As of the latest data, NextCell Pharma AB stock price is SEK 1.00, with a previous close of SEK 0.99. NextCell Pharma AB gained SEK 0.01 in the last trading session, representing a 0.5% increase.
What is NextCell Pharma AB (NXTCL) current market capitalization?
NextCell Pharma AB market cap is approximately 111.28 million.
What is NextCell Pharma AB (NXTCL) Earnings Per Share (EPS)?
The trailing EPS is -SEK 0.43, and the forward EPS is -SEK 0.40.
What is NextCell Pharma AB (NXTCL) EBITDA?
NextCell Pharma AB EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -10.01 million.
Does NextCell Pharma AB (NXTCL) pay dividends?
No. NextCell Pharma AB does not pay a dividend.
What is NextCell Pharma AB (NXTCL) beta (volatility) score?
NextCell Pharma AB has a beta of 0.730, indicating lower volatility than the overall market.